Clinical Trial Update: Acalabrutinib in CNSL [Phase 1, Phase 2]

View source ↗

Summary

Acalabrutinib is being studied in a Phase 1/2 trial for Central Nervous System Lymphoma, including refractory and recurrent CNS lymphoma. The study is currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• Acalabrutinib (acalabrutinib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Central Nervous System Lymphoma, Refractory Central Nervous System Lymphoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING